New interleukin inhibitor

Novartis has launched a new interleukin inhibitor, Ilaris (canakinumab) for the treatment of cryopyrin-associated periodic syndromes (CAPS).

It is suitable for use in adults, adolescents and children aged 4 years and older with a body weight above 15kg. The recommended dose is 150mg in patients over 40kg and 2mg/kg for those between 15 and 40kg.

Ilaris is administered as a single dose via subcutaneous injection once every eight weeks. Treatment should be initiated and supervised by a specialist experienced in the diagnosis and management of CAPS.

View Ilaris drug record

Further information: Novartis Pharmaceuticals

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases